|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
|
DE59010908D1
(de)
|
1989-09-12 |
2000-08-10 |
Hoffmann La Roche |
TNF-bindende Proteine
|
|
EP0553186B1
(de)
*
|
1990-09-28 |
1999-09-01 |
Immunex Corporation |
Verfahren zur herstellung th-unabhängiger zytotoxischer t-zymphozyten
|
|
US5470730A
(en)
*
|
1990-09-28 |
1995-11-28 |
Immunex |
Method for producing TH -independent cytotoxic T lymphocytes
|
|
DE69333027T2
(de)
*
|
1992-03-30 |
2004-05-06 |
Immunex Corp., Seattle |
Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
|
|
US5538863A
(en)
*
|
1993-07-01 |
1996-07-23 |
Immunex Corporation |
Expression system comprising mutant yeast strain and expression vector encoding synthetic signal peptide
|
|
AU729873B2
(en)
*
|
1993-12-14 |
2001-02-15 |
University Of Pittsburgh |
Systemic gene treatment of connective tissue diseases
|
|
AU690743B2
(en)
*
|
1994-09-05 |
1998-04-30 |
Walter And Eliza Hall Institute Of Medical Research, The |
A novel haemopoietin receptor
|
|
US6274708B1
(en)
|
1994-09-05 |
2001-08-14 |
Amrad Operations Pty Ltd. |
Mouse interleukin-11 receptor
|
|
CA2225378C
(en)
|
1995-06-29 |
2012-04-17 |
Immunex Corporation |
Cytokine that induces apoptosis
|
|
US6384203B1
(en)
|
1999-05-12 |
2002-05-07 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
|
ATE332373T1
(de)
|
1998-08-21 |
2006-07-15 |
Immunex Corp |
Menschlisches il-1 epsilon dna und polypeptide
|
|
EP1939297A1
(de)
|
1998-09-24 |
2008-07-02 |
Pharmacia & Upjohn Company LLC |
Alzheimerkrankheit-Sekretase
|
|
US6472179B2
(en)
*
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
|
US6693172B1
(en)
|
1999-05-27 |
2004-02-17 |
Pharmacia And Upjohn Company |
Double mutant alpha-7 nicotinic acetylcholine receptor
|
|
US6455290B1
(en)
|
1999-07-09 |
2002-09-24 |
Pharmacia Italia S.P.A. |
Tankyrase homolog protein (THP), nucleic acids, and methods related to the same
|
|
EP1222273A2
(de)
|
1999-10-22 |
2002-07-17 |
PHARMACIA & UPJOHN COMPANY |
G-protein gekoppelten rezeptoren aus drosophila, nukleinsäuren und zugehörigen verfahren
|
|
CA2394015C
(en)
|
1999-12-20 |
2013-11-05 |
Immunex Corporation |
Tweak receptor
|
|
US6498026B2
(en)
|
2000-02-25 |
2002-12-24 |
Hercules Incorporated |
Variant galactose oxidase, nucleic acid encoding same, and methods of using same
|
|
WO2001090326A2
(en)
|
2000-05-22 |
2001-11-29 |
Pharmacia & Upjohn Company |
Novel matrix metalloproteinases
|
|
US7259244B2
(en)
|
2000-06-16 |
2007-08-21 |
Nerviano Medical Sciences S.R.L. |
Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
|
|
US6686449B2
(en)
|
2000-06-30 |
2004-02-03 |
Pharmacia & Upjohn Company |
Mutant presenilin 1 polypeptides
|
|
US7067626B2
(en)
|
2000-07-05 |
2006-06-27 |
Pharmacia & Upjohn Company |
Human ion channel proteins
|
|
US6652854B2
(en)
|
2000-08-08 |
2003-11-25 |
Immunex Corporation |
Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
|
|
US20030049255A1
(en)
*
|
2001-08-07 |
2003-03-13 |
Sims John E. |
Interleukin-1 receptors in the treatment of diseases
|
|
JP2005523681A
(ja)
|
2001-10-04 |
2005-08-11 |
イミュネックス・コーポレーション |
Ul16結合タンパク質4
|
|
ES2557741T3
(es)
|
2002-03-27 |
2016-01-28 |
Immunex Corporation |
Procedimientos para incrementar la producción de polipéptidos
|
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
|
JP2007500132A
(ja)
|
2003-07-25 |
2007-01-11 |
アムジェン インコーポレイテッド |
Ldcamのアンタゴニストおよびアゴニスト、並びにその使用法
|
|
ATE465172T1
(de)
|
2004-03-05 |
2010-05-15 |
Univ Illinois |
Peptidträger für die verabreichung von arzneimitteln
|
|
US7582442B2
(en)
|
2004-03-16 |
2009-09-01 |
The Regents Of The University Of Michigan |
Methods and compositions for using aleveolar macrophage phospholipase A2
|
|
US7319015B2
(en)
|
2004-03-16 |
2008-01-15 |
The Regents Of The University Of Michigan |
Methods and compositions for using alveolar macrophage phospholipase A2
|
|
WO2005116069A2
(en)
|
2004-04-14 |
2005-12-08 |
Monell Chemical Senses Center |
Taste receptors of the t1r family from domestic dog
|
|
EP2520310B1
(de)
|
2004-04-23 |
2016-03-30 |
Zoetis Services LLC |
Zellulärer Permissivitätsfaktor für Viren und seine Verwendungen
|
|
WO2006011646A1
(ja)
*
|
2004-07-27 |
2006-02-02 |
Riken |
N-デアセチラーゼ/n-スルホトランスフェラーゼ2を発現するベクター
|
|
KR20070009269A
(ko)
|
2005-07-15 |
2007-01-18 |
한국생명공학연구원 |
재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
|
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
|
EP2500416A1
(de)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Verbesserungen an Zellkulturen
|
|
TW201516149A
(zh)
|
2006-09-13 |
2015-05-01 |
Abbvie Inc |
細胞培養改良
|
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
|
JP5718640B2
(ja)
|
2007-08-21 |
2015-05-13 |
アムジエン・インコーポレーテツド |
ヒトc−fms抗原結合性タンパク質
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
|
JP2009183176A
(ja)
*
|
2008-02-05 |
2009-08-20 |
Univ Of Tokyo |
Il−1タイプiiレセプター遺伝子の欠損変異体マウス
|
|
GB0803076D0
(en)
|
2008-02-20 |
2008-03-26 |
Univ Ghent |
Mucosal Membrane Receptor and uses thereof
|
|
WO2010002895A2
(en)
|
2008-06-30 |
2010-01-07 |
The Regents Of The University Of Michigan |
Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
|
|
WO2010024927A2
(en)
|
2008-08-28 |
2010-03-04 |
The Research Foundation Of State University Of New York |
Treatment of amyloidoses using myelin basic protein and fragments thereof
|
|
EP2918606B1
(de)
|
2008-12-04 |
2018-07-11 |
Korea Research Institute of Bioscience and Biotechnology |
Screening von abundant sezernierten Proteinen und deren Verwendung als Fusionspartner zur Herstellung rekombinanter Proteine
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
US9052304B2
(en)
|
2009-03-13 |
2015-06-09 |
Terrasep, Llc |
Methods and apparatus for centrifugal liquid chromatography
|
|
EP2432493A1
(de)
|
2009-05-20 |
2012-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verwendung von il-17-polypeptiden zur verwendung bei der prävention oder behandlung von atherosklerose
|
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
WO2011054916A1
(en)
|
2009-11-06 |
2011-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of atherosclerosis
|
|
RU2579977C2
(ru)
|
2009-11-13 |
2016-04-10 |
Грифольс Терапьютикс Инк. |
СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
ES2477498T3
(es)
|
2010-01-20 |
2014-07-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular
|
|
WO2011127418A1
(en)
|
2010-04-09 |
2011-10-13 |
Amgen Inc. |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
|
WO2011130417A2
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
|
|
WO2012019160A1
(en)
|
2010-08-05 |
2012-02-09 |
Amgen Inc. |
Dipeptides to enhance yield and viability from cell cultures
|
|
WO2012042289A1
(en)
|
2010-09-28 |
2012-04-05 |
Inserm ( Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of bone density related diseases
|
|
US20140105898A1
(en)
|
2011-02-28 |
2014-04-17 |
Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo |
Apoptosis-inducing molecules and uses therefor
|
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
|
US9133493B2
(en)
|
2011-04-21 |
2015-09-15 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
|
ES2560012T3
(es)
|
2011-05-10 |
2016-02-17 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
SI2726600T1
(sl)
|
2011-07-01 |
2017-07-31 |
Amgen Inc. |
Sesalska celična kultura
|
|
WO2013009971A1
(en)
|
2011-07-12 |
2013-01-17 |
E. I. Du Pont De Nemours And Company |
Detection and screening method and materials useful in performance thereof
|
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
|
WO2013033600A1
(en)
|
2011-09-02 |
2013-03-07 |
Amgen Inc. |
Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
|
|
AP2014007588A0
(en)
|
2011-09-22 |
2014-04-30 |
Amgen Inc |
CD27L antigen binding proteins
|
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
|
US9381229B2
(en)
|
2011-11-28 |
2016-07-05 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Pharmaceutical composition for use in the treatment of dysfunction associated with aging
|
|
WO2013086443A1
(en)
|
2011-12-08 |
2013-06-13 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
|
CN104507968B
(zh)
|
2012-04-27 |
2019-02-05 |
诺和诺德股份有限公司 |
人cd30配体抗原结合蛋白
|
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
|
EP3434276B1
(de)
|
2012-06-06 |
2024-10-30 |
Pepkon |
Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von krebs
|
|
US20150166630A1
(en)
|
2012-07-19 |
2015-06-18 |
Amgen Inc. |
Btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
HK1210809A1
(en)
|
2012-12-07 |
2016-05-06 |
北卡罗来纳州大学 |
Beta-hexosyl-transferases and uses thereof
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
|
WO2014159764A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
|
PL3395423T3
(pl)
|
2013-03-14 |
2024-03-18 |
Amgen Inc. |
Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
TWI771890B
(zh)
|
2013-03-14 |
2022-07-21 |
美商安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
JP6469644B2
(ja)
|
2013-03-15 |
2019-02-13 |
アムジエン・インコーポレーテツド |
抗ccr7抗原結合タンパク質に関係する方法および組成物
|
|
KR102215405B1
(ko)
|
2013-03-15 |
2021-02-10 |
암젠 인크 |
인간 pac1 항체
|
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
|
HUE056580T2
(hu)
|
2013-05-30 |
2022-02-28 |
Kiniksa Pharmaceuticals Ltd |
Onkosztatin-M-receptor antigénjét kötõ fehérjék
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3712166A1
(de)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen
|
|
WO2015048272A1
(en)
|
2013-09-25 |
2015-04-02 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
SI3063287T1
(sl)
|
2013-10-31 |
2025-06-30 |
Amgen, Inc. |
Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov
|
|
WO2015086727A2
(en)
|
2013-12-11 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New prognostic method for patients suffering of a cancer
|
|
MX376230B
(es)
|
2014-01-13 |
2025-03-07 |
Amgen Inc |
Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
|
|
CN106170554B
(zh)
|
2014-01-29 |
2021-08-17 |
美国安进公司 |
过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
|
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
|
CA3177696A1
(en)
|
2014-02-20 |
2015-08-27 |
Allergan, Inc. |
Complement component c5 antibodies
|
|
AU2015223056B2
(en)
|
2014-02-27 |
2020-10-01 |
Allergan, Inc. |
Complement Factor Bb antibodies
|
|
KR102391259B1
(ko)
|
2014-06-04 |
2022-04-26 |
암젠 인크 |
포유류 세포 배양물을 회수하는 방법
|
|
UY36302A
(es)
|
2014-09-15 |
2016-04-29 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
|
|
ES2962593T3
(es)
|
2014-11-19 |
2024-03-20 |
Amgen Inc |
Cuantificación de resto glucano en glucoproteínas recombinantes
|
|
CA2969225C
(en)
|
2014-12-01 |
2023-08-22 |
Amgen Inc. |
Process for manipulating the level of glycan content of a glycoprotein
|
|
EP3273981B1
(de)
|
2015-03-24 |
2020-04-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von diabetes
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
TWI728953B
(zh)
|
2015-04-24 |
2021-06-01 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
JP6932700B2
(ja)
|
2015-09-15 |
2021-09-08 |
アムジエン・インコーポレーテツド |
4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
|
|
EP3353288A1
(de)
|
2015-09-22 |
2018-08-01 |
H. Hoffnabb-La Roche Ag |
Expression von fc-haltigen proteinen
|
|
CN108431026B
(zh)
|
2015-11-02 |
2023-02-17 |
豪夫迈·罗氏有限公司 |
制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
|
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
|
CN117106085A
(zh)
|
2015-12-23 |
2023-11-24 |
美国安进公司 |
使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
|
|
KR20240115933A
(ko)
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
US11312745B2
(en)
|
2016-07-22 |
2022-04-26 |
Amgen Inc. |
Methods of purifying Fc-containing proteins
|
|
AU2017356317A1
(en)
|
2016-11-14 |
2019-05-30 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
|
US12049493B2
(en)
|
2017-01-06 |
2024-07-30 |
Abl Bio Inc. |
Anti-alpha-synuclein antibodies and uses thereof
|
|
WO2018128454A1
(ko)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
항 α-SYN 항체 및 그 용도
|
|
EP4480537A3
(de)
|
2017-01-17 |
2025-03-12 |
Amgen Inc. |
Verfahren zur behandlung oder linderung von stoffwechselerkrankungen mit glp-1-rezeptoragonisten, die mit antagonisten für den magenhemmenden peptidrezeptor (gipr) konjugiert sind
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
|
CA3062194A1
(en)
|
2017-06-20 |
2018-12-27 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
|
JP7250706B2
(ja)
|
2017-06-21 |
2023-04-03 |
アムジエン・インコーポレーテツド |
胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
EP3658581A1
(de)
|
2017-07-24 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antikörper und peptide zur behandlung von erkrankungen im zusammenhang mit hcmv
|
|
MA68842B1
(fr)
|
2017-08-04 |
2025-01-31 |
Amgen Inc. |
Procédé de conjugaison de cys-mabs
|
|
BR112020011875A2
(pt)
|
2017-12-14 |
2020-11-24 |
Abl Bio Inc. |
anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
|
|
JP7339262B2
(ja)
|
2018-01-12 |
2023-09-05 |
アムジェン インコーポレイテッド |
Pac1抗体及びその使用
|
|
IL307155B2
(en)
|
2018-05-01 |
2025-11-01 |
Amgen Inc |
Antibodies with modulated glycan profiles
|
|
WO2019225777A1
(ko)
|
2018-05-23 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-ror1 항체 및 그 용도
|
|
WO2020070235A1
(en)
|
2018-10-04 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to restore or improve cognitive functions
|
|
HUE068630T2
(hu)
|
2018-12-10 |
2025-01-28 |
Amgen Inc |
Mutáns PiggyBac transzpozáz
|
|
AU2020283890A1
(en)
|
2019-05-30 |
2021-12-16 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
|
WO2020264384A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
|
CN114555634B
(zh)
|
2019-08-13 |
2025-01-10 |
美国安进公司 |
用于扩增调节性t细胞的白介素-2突变蛋白
|
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
|
CA3160482A1
(en)
|
2019-11-08 |
2021-05-14 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
|
US20230047631A1
(en)
|
2019-11-19 |
2023-02-16 |
Amgen Inc. |
Novel multispecific antibody format
|
|
PE20221506A1
(es)
|
2019-12-17 |
2022-10-04 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
JP2023526655A
(ja)
|
2020-05-19 |
2023-06-22 |
ノース カロライナ ステート ユニバーシティ |
ヒトミルクオリゴ糖を産生するための組成物及び方法
|
|
EP4200338A1
(de)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigenbindende proteine mit nichtkanonischem disulfid in der fab-region
|
|
EP4225786A2
(de)
|
2020-10-07 |
2023-08-16 |
Amgen Inc. |
Rationale auswahl von bausteinen zur anordnung multispezifischer antikörper
|
|
US20230323287A1
(en)
|
2020-10-30 |
2023-10-12 |
Amgen Inc. |
Overexpression of insulin-like growth factor receptor mutants to modulate igf supplementation
|
|
EP4244246A1
(de)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Neue linker von multispezifischen antigenbindenden domänen
|
|
US20240182600A1
(en)
|
2021-04-20 |
2024-06-06 |
Amgen Inc. |
Balanced Charge Distribution in Electrostatic Steering of Chain Pairing in Multi-specific and Monovalent IgG Molecule Assembly
|
|
US20240209115A1
(en)
|
2021-04-29 |
2024-06-27 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
|
WO2022261299A1
(en)
|
2021-06-10 |
2022-12-15 |
Amgen Inc. |
Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
|
|
TW202328442A
(zh)
|
2021-09-10 |
2023-07-16 |
美商安進公司 |
平臺宿主對igf—培養基之適應
|
|
KR20240128067A
(ko)
|
2021-12-29 |
2024-08-23 |
브리스톨-마이어스 스큅 컴퍼니 |
랜딩 패드 세포주의 생성
|
|
AU2023231637A1
(en)
|
2022-03-09 |
2024-09-05 |
Amgen Inc. |
Optimized transfection protocol
|
|
US20250163116A1
(en)
|
2022-03-16 |
2025-05-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat infectious diseases
|
|
EP4406973A1
(de)
|
2023-01-27 |
2024-07-31 |
Fundació Privada Institut de Recerca de la SIDA-Caixa |
Antikörper und verwendungen davon zur behandlung von infektionen durch eingehüllte viren
|
|
EP4735476A1
(de)
|
2023-06-27 |
2026-05-06 |
Amgen Inc. |
Ladungspaarmutationen zur ermöglichung der korrekten schwerleichtkettenpaarung
|
|
AU2024300966A1
(en)
|
2023-07-21 |
2026-01-08 |
Amgen Inc. |
Vectors incorporating a combination of promoters driving selectable marker expression
|
|
WO2025025208A1
(zh)
*
|
2023-08-03 |
2025-02-06 |
苏州系统医学研究所 |
抗il1r2的抗体、其抗原结合片段及应用
|
|
AU2024363859A1
(en)
|
2023-10-18 |
2026-04-09 |
Amgen Inc. |
Evaluation of mrna transcript levels using ddpcr for early pool and single-cell clone assessment in cell line development
|
|
CN122580338A
(zh)
|
2024-01-19 |
2026-08-14 |
安进公司 |
具有两个轻链拷贝的表达载体系统
|
|
TW202547524A
(zh)
|
2024-01-19 |
2025-12-16 |
美商安進公司 |
用於多組形式的體積生產率提高和雜質形成減少的載體工程策略
|
|
IL328989A
(en)
|
2024-01-23 |
2026-08-01 |
Amgen Inc |
Methods for cargo variant modulation of monoclonal antibodies
|
|
WO2025184493A1
(en)
|
2024-02-29 |
2025-09-04 |
Amgen Inc. |
Dual selection expression vector systems for multi-chain biologics
|
|
WO2025199030A1
(en)
|
2024-03-18 |
2025-09-25 |
Amgen Inc. |
Glp-1 receptor agonists and their medical use
|
|
WO2026117415A1
(en)
|
2024-11-27 |
2026-06-04 |
Genentech, Inc. |
Afucosylation modification
|